If at first you don't succeed, dust yourself off and try again.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Added a small amount more. Think I’ll add in small increments as it drops. Announcement of new contracts could send it.
Added some more today.
Bought some at $2.70 today.
$ALAR I’m starting a position and will probably keep adding. Still growing. Was profitable two of last three quarters. Still a microcap so still has tons of room to run. Seems like interest in their product should only increase as need for data increases with AI.
$LPSN Shrinking revenue could drop the share price more. I do like the price to sales ratio of 0.30 which is extremely low. And cash per share is $1.63 which is above the current share price. But they need to either slow the bleeding revenue or become consistently profitable to attract more investor interest. Signing a new big client would be helpful to show progress. Lots of companies will be moving to conversational AI to answer internal questions especially stuff like HR related questions, so there are lots of opportunities for growth. Live Person is not the only company in this space. If clients have internal rollouts that are successful I would not be surprised for them to start using it for external clients as well. I see it as a fairly risky investment but could really be a big winner if they improve their client retention.
Yeah Jan 2026 calls pretty cheap too. Thinking about grabbing some.
Yeah I’m still holding. Not terrible either. Need better growth or become profitable consistently to draw more investors in.
Still holding. Turning out to be a good investment.
Been a beast lately. Healthy pullback last few days.
DBRG new 52 week low today $12.13
Starting a position. Should start to move higher soon I would guess.
Yeah really strong lately.
Looking good lately. I wonder if they drop it on earnings but would use it as a good opportunity to add.
Up 11% this week. Very good week.
Weak price action since it’s been on the nasdaq. Hopefully can turn that around soon.
I think this is a great price to accumulate shares. Thinking about grabbing some warrants too GRABW.
Looking good so far. Still holding. 20% short interest according to fintel.
Thanks good luck to you. Warrants not a bad option I don’t think.
Great growth as well.
Starting to buy GRAB. Just went profitable and implementing a share buyback.
Started buying some around $6.50. I think when the Fed finally starts lowering rates this will move.
Looks like it might be a good long term
Hold at $7.
Good question.
Nice thanks for the info.
Should get per ten pre-split shares converted:
1 CORZ = $4
2.5 CORZW = $1.40*2.5 = $3.5
2.1 CORZZ = $2.10*2.1= $4.41
Total current value should receive per 10 shares = $4 + $3.5 + $4.41 = $11.91. So shares pre-split are essentially trading at $1.19 currently
I think this is why CORZQ dropped. The share price up through yesterday was inclusive of the warrants people will be getting. And since if you bought shares today you won’t be getting warrants after the reverse split, the share price went down by the assumed value of the warrants post reverse split. Makes sense.
Tomorrow will be interesting
Wow just saw. Not sure yet why the big drop.
$BTC.X $IBIT
The second-highest trading volume was recorded by BlackRock's iShares $IBIT ETF, which started with an AUM (assets under management)of $10 million and issued 400,000 shares.
https://www.ishares.com/us/products/333011/ishares-bitcoin-trust
IBIT went from 227.9 BTC and no cash yesterday to now 2,620.59 BTC and $111,912,401 in cash.
10x the bitcoin and 10x amount of cash of total AUM after one day. Interesting the price got hammered.
BTC ETF approved.
WASHINGTON/NEW YORK, Jan 10 (Reuters) - The U.S. securities regulator on Wednesday approved the first U.S-listed exchange traded funds (ETFs) to track bitcoin, its Chair Gary Gensler said, in a watershed for the world's largest cryptocurrency and the broader crypto industry.
The agency approved applications, including from BlackRock BLK.N, Ark Investments and 21Shares ABTC.S, Fidelity, Invesco IVZ.N, and VanEck, among others, according to a notice on its website. Some products are expected to begin trading as early as Thursday.
Will there still be a reverse split with the share price gaining so much?
The Company currently has a Bitcoin mining market share of approximately 0.66% (.965Exahash/147.315Exahash), with an estimated mining output of over six Bitcoins per day, a daily value of in excess of US$222,000.
Bitfarms is on schedule to install 3,000 additional miners at the end of this month. Upon successful completion of these installations, the Company will have installed 8,847 latest generation miners since June 2020. As a result of this growth, the Company will have added over 679 Petahash per second (“PH”) of computational power to its mining operations within the past eight months.
Most undervalued miner. Loaded at $5. Will add if it drops. I’m thinking it can 5-10x when it is listed on the Nasdaq.
Nice. Let us know if you hear back.
Closing of offering announced.
http://www.globenewswire.com/news-release/2021/02/12/2175175/0/en/Enlivex-Announces-Closing-of-Previously-Announced-Bought-Deal-Offering-of-Approximately-46-0-Million-Ordinary-Shares.html http://www.globenewswire.com/news-release/2021/02/12/2175175/0/en/Enlivex-Announces-Closing-of-Previously-Announced-Bought-Deal-Offering-of-Approximately-46-0-Million-Ordinary-Shares.html
Nice Ark added 23k ENLV. 411k shares now
Sepsis would be a $30b total addressable market, where there is not a great treatment right now. Non-covid ARDS would be $15b TAM
Seems way undervalued for how well all trials have gone thus far. Only $330 mil market cap right now.
No don’t think so.
ENLV Covid-19 Treatment. It works.
ENLV Covid-19 Treatment ?? ?? ??
First-time DD post here. The play in Enlivex, or ENLV. Owned by ARK and Cathie has been adding heavy lately. As of February 10, 2021, Ark has 373k shares of ENLV, after adding 37k on Wednesday. ?? ?? ??
ELVN is a biotech company that is developing a drug for sepsis, Allocetra. Allocetra is a drug meant to treat the overreaction of the immune system. So the geniuses at Enlivex thought, hey, maybe this will work for covid-19, by preventing the body from over-reacting and cytokine storm from happening, thus stopping the worst of covid-19. The treatment infuses billions of early apoptotic cells, or dying cells, into the bloodstream. Macrophages and dendritic cells, the body’s first responders, feed on these apoptotic cells, releasing fewer cytokine alert signals and calming the storm. The study drug, Allocetra-OTS, is based on the known activity of apoptotic cells to contribute to maintenance of peripheral immune homeostasis. An altered immune response is associated with organ dysfunction in sepsis, so the possibility is being tested that the study drug can improve the condition of sepsis. Sepsis is a big deal. But first see what it did for covid-19 in Phase Ib and Phase II trials.
Phase II + Ib (21 patients treated)
11/21 (52%) with severe illness10/21 (48%) with critical illness0/21 (0%) mortality on day-28 19/21 (90.5%) patients recovered and were discharged from the hospital by day-28 Average duration of hospitalization post administration of AllocetraTM for discharged patients was 5.6 days 2/21 (9.5%) patients, both of whom had critical illness at the time of AllocetraTM treatment, were hospitalized in the ICU on a respirator on day-28
100% survival rate for severe and critical patients
[https://www.globenewswire.com/news-release/2020/12/03/2139086/0/en/Enlivex-Reports-Positive-Interim-Results-From-Phase-II-Clinical-Trial-Evaluating-Allocetra-in-Severe-and-Critical-COVID-19-Patients.html](https://www.globenewswire.com/news-release/2020/12/03/2139086/0/en/Enlivex-Reports-Positive-Interim-Results-From-Phase-II-Clinical-Trial-Evaluating-Allocetra-in-Severe-and-Critical-COVID-19-Patients.html)
Check out their January 2021 investor presentation here: [https://enlivex.com/wp-content/uploads/2021/01/enlivex-investor-presentation-jan-2021.pdf ](https://enlivex.com/wp-content/uploads/2021/01/enlivex-investor-presentation-jan-2021.pdf)
The investor presentation shows the covid-19 related market size as $1 billion, but the real kicker is if it gets approved for sepsis, because that is a $30 billion market. The sepsis market is 30x that of the covid-19 market. Allocetra has also shown efficacy for sepsis.And $ENLV market cap is only $332 million. Way undervalued with the potential and positive results for Allocetra.
Here is some data from the Phase I trials for sepsis:
The Acute Physiology and Chronic Health Evaluation (APACHEII) score of the AllocetraTM-treated group was 12.9, and the corresponding probability of mortality of at least one patient in that group was predicted at 85% based on the hospital ICU staff’s clinical assessment of that patient’s overall condition at admission. However, none (0%) of the AllocetraTM-treated patients died during the 28-day study period, as compared to 27% mortality in the matched control group during the same 28-day period. Each of the 10 AllocetraTM-treated patients had between 2 to 5 dysfunctional organ systems upon admission to the ICU. All (100%) of the AllocetraTM-treated patients had rapid and complete recovery from their septic conditions and any organ dysfunction that was present upon admission to the ICU. Despite the similar SOFA score at admission between the AllocetraTM-treated patients and the matched controls (average of 3.4 versus 3.47), no AllocetraTM-treated patients had an increase in organ-failure state post AllocetraTM treatment, while the majority of matched controls had an increase in organ-failure state. The average worsening in organ-failure state of patients in the matched control group was approximately 100% compared with their initial ICU hospitalization state vs 0% percent worsening in the organ-failure state of AllocetraTM-treated patients after treatment (p<0.0001). The ICU length-of-stay for all AllocetraTM-treated patients was significantly shorter than those patients who received only the standard of care, with an average of 4.7 days compared to 11.1 days in the matched controls group, a 58% reduction (p<0.0001). The slowest ICU discharge of a patient treated with AllocetraTM was after 8 days, while approximately 50% of the matched controls group remained in the ICU after 21 days.
Another 100% survival rate.
This really seems to be a miracle drug for these diseases.
Positions: March 2021 $25 calls, May 2021 $25 calls, and shares
Not investment advice. Not a financial advisor.
Nice. In big today around $20